| Developers: | Biomarker-ru |
| Last Release Date: | 2020/09/17 |
| Branches: | Pharmaceutics, medicine, health care |
Main articles:
ARNA Breast is the test for early diagnosis of a breast cancer.
2020: Attraction of 3.5 million dollars on development of the test for early diagnosis of a breast cancer
On September 17, 2020 the Biomarker-ru company reported that it closed a round And of 3.5 million dollars on development and promotion of ARNA Breast. The lead investor acted Xploration Capital venture fund of Igor Kim and Evgeny Timko.
According to the company, Biomarker-ra develops test systems for early detection of oncological diseases of method of detection of specific fragments of nucleinic acids in blood plasma.
Within the research conducted based on I.M. Sechenov First Moscow State Medical University, the ARNA Breast test showed accuracy more than 90%. Read more here.
The ARNA Breast test consists of two parts. The first is based on DNA, the second on proteins. The genetic protocol provides quantitative analysis of fragments of DNA in blood which remained after disintegration of cages. When using precision technologies it allows to identify a disease with a necessary accuracy. The proteinaceous activity revealed Biomarker-ra has the status "-it is new" and for September, 2020 is in a patenting stage.
| The site content is translated by machine translation software powered by PROMT. The machine-translated articles are not always perfect and may contain errors in vocabulary, syntax or grammar. Read original article If you find inaccuracies or errors in the results of machine translation, please write to editor@tadviser.ru. We will make every effort to correct them as soon as possible. |